Respiratory infections are common precursors to asthma exacerbations in children, but molecular immune responses that determine whether and how an infection causes an exacerbation are poorly understood. By using systems-scale network analysis, we identify repertoires of cellular transcriptional pathways that lead to and underlie distinct patterns of asthma exacerbation. Specifically, in both virus-associated and nonviral exacerbations, we demonstrate a set of core exacerbation modules, among which epithelial-associated SMAD3 signaling is upregulated and lymphocyte response pathways are downregulated early in exacerbation, followed by later upregulation of effector pathways including epidermal growth factor receptor signaling, extracellular matrix production, mucus hypersecretion, and eosinophil activation. We show an additional set of multiple inflammatory cell pathways involved in virus-associated exacerbations, in contrast to squamous cell pathways associated with nonviral exacerbations. Our work introduces an in vivo molecular platform to investigate, in a clinical setting, both the mechanisms of disease pathogenesis and therapeutic targets to modify exacerbations.
xacerbations are the primary cause of morbidity and mortality in children with asthma and occur despite current treatments. It has been established that the majority of exacerbations are provoked by viral respiratory infections, most notably rhinoviruses (RVs); however, exacerbations also occur in the absence of infections 1, 2 . Furthermore, even in children with severe asthma, the majority of respiratory infections do not progress to exacerbation 3 . The fundamental question of why some but not all colds lead to exacerbations has not been fully answered, and the similarities and differences between the mechanism(s) of virus-associated and nonviral exacerbations are unknown. Identifying the molecular pathways underlying progression from colds to exacerbations has the potential to improve understanding of the mechanisms of these events and, from this information, to target therapeutic strategies more precisely and effectively.
Beneficial effects in exacerbation prevention have been seen with type 2 and eosinophil-modulating monoclonal antibodies, supporting the importance of related pathways [4] [5] [6] . However, these therapies reduce, rather than eliminate, exacerbations and do not correct the physiological abnormalities of asthma, thereby confirming the contribution of additional factors to the genesis of exacerbations 7 .
Respiratory epithelial inflammation, in particular IL- 33 signaling, has been demonstrated to have an important role in RV-induced exacerbations 8 . Several additional immune pathways have been linked to asthma exacerbations, generally through targeted investigations 9 . Current evidence has yet to fully establish how multiple interacting molecular pathways may lead to asthma exacerbations.
Systems-scale data collection and network analysis facilitates unbiased mechanistic disease research 10 . This approach has added novel information to the understanding of asthma [11] [12] [13] [14] ; however, previous asthma 'omics' studies have not been designed to determine molecular networks specific to asthma exacerbations. We have therefore performed the first study in asthma that uses transcriptome network analysis in a case-control, longitudinal study design. In our study, we prospectively evaluated a cohort of children with high disease burden. We combined nasal virus PCR, nasal and peripheral blood cell differentials, and nasal and blood RNA-seq for serial sample collections at baseline and longitudinally during episodes when participants reported cold symptoms to determine the key molecular pathways associated with subsequent asthma exacerbations. We combined cell deconvolution, weighted gene correlation network analysis (WGCNA), and linear mixed-effects
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ResouRce NATuRe IMMuNOlOgy modeling to establish the repertoires of cellular transcriptional pathways underpinning asthma exacerbations, including distinct pathways in virus-associated and nonviral exacerbations, the kinetics of these pathways leading to exacerbations, predictors of exacerbation risk, and the responses to systemic corticosteroid therapy. Our results constitute an unbiased, detailed, and sensitive systemslevel mechanistic summary that substantially advances understanding of the immunopathogenesis of asthma exacerbations. Moreover, these methods provide a framework for in vivo investigation of mechanisms of therapeutic intervention.
Results
Characterization of colds and exacerbations. We enrolled 208 children 6-17 years old with a daily inhaled corticosteroid (ICS) requirement of at least 500 μg of fluticasone (or the equivalent), a history of at least two exacerbations treated with systemic corticosteroids and/or hospitalization in the previous 12 months, and a blood eosinophil concentration of ≥150 cells/mm 3 . We collected nasal lavage and peripheral blood samples at enrollment after a period without cold symptoms or an asthma exacerbation (baseline) and again after the onset of a respiratory illness characterized by common cold symptoms (termed 'events'), including two samples within 6 d of cold symptom onset per event (Fig. 1 ). Each participant was followed for two events or 6 months.
The primary aim of the study was to identify patterns of gene expression induced during events that progressed to asthma exacerbations (exacerbation, Ex ). Of the 154 total events captured in 106 children, 47 were Ex + events and 107 were Ex -events. All Ex + events had one or two samples collected prior to initiation of systemic corticosteroids, and these samples were used for the primary analysis. When comparing the Ex + and Ex -events, there were no differences in demographic variables or in nasal or blood cell differentials (Table 1) . Virus PCR and partial sequencing were used to identify events associated with a respiratory virus (V + ) or virus-negative (V -) events; 66.2% of events had a detectable respiratory virus, and, of these, 53.9% were positive for RV-A or RV-C. However, there were no differences in virus frequency or type when comparing Ex + and Ex -events. Pulmonary functions were assessed at baseline and during events. Only Ex + events were associated with significant decline in forced expiratory volume in 1 s (FEV 1 ) predicted (%) and FEV 1 to forced vital capacity (FEV 1 /FVC) ratio, demonstrating a change in pathophysiological measures of lung function associated with the standardized clinical definition of asthma exacerbation used in the study (Fig. 2) .
These results confirm the high rate of asthma exacerbations associated with cold symptoms in this population and the corresponding pathophysiological changes associated with exacerbations.
Modular immune responses underlying asthma exacerbations.
From nasal and blood samples, we combined measured cell percentages with RNA-seq data and used cell deconvolution and WGCNA to construct and validate a repertoire of 94 distinct gene expression modules representing a diverse array of biological functions (Supplementary Fig. 1 and Supplementary Table 1) . Gene expression levels measured in nasal samples were associated with percentages of neutrophils, lymphocytes, macrophages, eosinophils, respiratory epithelial cells (termed 'epithelium'), and/or squamous epithelial cells (termed 'squamous') in nasal samples. Gene expression levels measured in peripheral blood were associated with percentages of neutrophils, lymphocytes, monocytes, eosinophils, and/or basophils in peripheral blood. By applying this modular framework, we compared Ex + and Ex -events to identify immune pathways underlying asthma exacerbations. Expression patterns in 13 nasal modules were statistically significantly associated with exacerbations at false-discovery rate (FDR) < 0.05, 11 of which had increased expression in Ex + events and 2 of which had decreased expression ( Table 2) ; 6 of these modules had FDR < 0.001 ( Fig. 3a and Supplementary Fig. 2a ). In contrast, there were no significant differences in expression for the blood modules. The comparison was adjusted for cell percentages and the presence or absence Fig. 3 ) but were not different between the Ex + and Ex -groups. Our results therefore suggest that the observed differences are predominantly due to changes in gene expression in specific cell types as opposed to changes in cell population composition. Each of the differentially expressed modules represents a significant protein-protein interaction network (enrichment P < 0.001) that includes important known asthma-associated genes but also demonstrates a much broader functional network ( Fig. 3b and Supplementary Fig. 2b) .
We annotated the most significant exacerbation-upregulated module as the epithelial-associated 'SMAD3-related cell differentiation' module, which was associated with epithelium and squamous percentages. It contains 46 genes that form a network centered around the transcription factor SMAD3 and includes other transcription factors and signaling molecules induced by transforming growth factor (TGF)-β1 signaling, including KLF4, FZD1, and FZD5, as well as genes involved in wound healing and epithelial differentiation. The second most significant upregulated module was annotated as 'eosinophil activation/mucus hypersecretion' . It contains 69 genes and was associated with eosinophil, epithelium, and squamous percentages; it includes the key epithelial mucin associated with hypersecretion, MUC5AC 15 , the respiratory epithelial proliferation marker KRT8 16 , the eosinophil surface activation/survival molecule CD9
17
, and the eosinophil transcription factor IKZF2 18 . FGFR2, a receptor implicated in dysregulation of epithelial-mesenchymal signaling in asthma 19 , represents the central-most gene within this module network. The third most significant upregulated module, 'extracellular matrix (ECM) production/cell membrane' , contains 209 genes and includes the asthma-associated collagen COL1A1 20 , the membrane molecules CAV1 and CFTR, and the inducible nitric oxide synthase NOS2
21
. The core gene of this network is EPHA1, a tyrosine kinase linked to pulmonary inflammation 22 . This module was associated with epithelium and squamous percentages. The fourth most significant upregulated module, 'epidermal growth factor receptor (EGFR) signaling/cell-cell adhesion' , contains 240 genes and represents an important pathway associated with lung fibrosis 23 and mucus secretion 24 . It forms a densely clustered network centered around EGFR and its homolog receptor ERBB2 and includes associated signaling molecules; it was associated with epithelium and squamous percentages.
The most significant module downregulated in exacerbation, 'lymphocyte proliferation' , was associated with nasal lymphocyte percentage and is a network of cell cycle genes. The other downregulated module was annotated as 'B cell receptor (BCR) signaling' and forms a network of both BCR signaling genes and genes related to mRNA translation; it was associated with lymphocyte percentage.
These results demonstrate upregulation of multiple respiratory epithelium-, squamous-, and eosinophil-associated responses and downregulation of lymphocyte-associated responses as molecular mechanisms in events that lead to asthma exacerbations as compared to those that resolve without exacerbation.
Validation of modular signatures associated with exacerbations.
To cross-validate these findings, the cohort was split into prespecified paired and unpaired analyses. The paired analysis demonstrated significant differences in expression patterns for seven nasal modules and the unpaired analysis demonstrated such differences for six nasal modules (FDR < 0.05). The top four most statistically significant modules with increased expression in Ex + events were the same in both comparisons (FDR < 0.05) and were the same modules observed in the full-cohort comparison discussed in the previous section. These modules showed a statistically similar level of difference in expression in each independent comparison. Similarly, the top two modules with decreased expression in Ex + events were the same in each comparison and the same modules found in the full-cohort comparison and discussed in the previous section. In the larger unpaired cohort, each of these modules met a stringent significance threshold of FDR < 0.05; in the smaller paired cohort, they were each borderline significant with FDR values of 0.06 and 0.22 ( Supplementary Fig. 4a ).
To further test the robustness of our findings, we performed a bootstrap sensitivity analysis through iterative subsetting of the full population. The same six modules were significant with Supplementary Fig. 4b,c ). These results demonstrate the consistency of these six exacerbation-associated pathways within and across individuals; given the robust and reproducible nature of the involvement of these six modules in exacerbation, we refer to them as 'core' exacerbation modules.
Differential patterns of immune response in virus-associated and nonviral asthma exacerbations. The presence or absence of a respiratory virus was a primary source of variability in our transcriptome data. Consequently, we sought to define molecular signatures of exacerbation common or specific to virus-associated and nonviral events. Events were subgrouped as V + Ex + (n = 33), In primary analysis, 13 (of 94 total) modules had significantly different expression when comparing the Ex + and Ex -event groups in the full cohort (FDR < 0.05). Values correspond to the differences shown graphically in Fig. 3 and Supplementary Fig. 2 . In secondary analysis, 20 modules had significantly different expression when comparing the V + Ex + , V + Ex -, V -Ex + , and V -Ex -subgroups (ANOVA, FDR < 0.05). These results are subdivided into virus-associated exacerbation modules that had different expression in the V + Ex + and V + Ex -subgroups and nonviral exacerbation modules that had different expression in the V -Ex + and V -Ex -subgroups. Values correspond to the differences shown graphically in Supplementary Fig. 5 . Another five modules were significant in this comparison but only showed different expression between V + and V -events with no difference according to exacerbation status; these modules are therefore excluded for brevity. The analysis included 247 unique nasal samples and 256 unique blood samples from 106 individuals who in total had 47 Ex + events and 107 Ex -events. The event subgroups included 33 V + Ex + , 14 V -Ex + , 69 V + Ex -, and 38 V -Ex -events. Modules are listed according to their summary annotation from Supplementary Table 2 , along with the source sample type (nasal or blood), cell type association based on deconvolution, and number of genes in the module. The first block of rows includes the six core modules that were significant in the primary and secondary analyses as well as the sensitivity analyses. The second block of rows includes those modules specific to V + Ex + events. The third block of rows includes those modules specific to V -Ex + events. Comparisons were performed by using a weighted linear model and empirical Bayes method, including terms for exacerbation status, cell percentages, presence or absence of virus, visit, and library sequencing depth with a random effect included for participant. For subgroup comparisons, presence or absence of virus was removed from the model and ANOVA was run to determine an overall significance value; pairwise comparisons were then run to determine significant differences across groups. 
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, and V -Ex -(n = 38). Similar virus types were observed in each V + subgroup; 60.6% of V + Ex + and 50.7% of V + Ex -events were positive for either RV-A or RV-C (Supplementary Table 2) .
After adjusting for cell percentages, 25 modules had significantly different expression among the groups (FDR < 0.05) ( Table 2) . Expression of the six previously defined core exacerbation modules was significantly different in both the V + Ex + and V -Ex + subgroups in comparison to the respective Ex -subgroups and the expression magnitudes were statistically similar in the Ex + subgroups, further confirming that these pathways are core to exacerbations, regardless of the apparent subgroup or inciting event ( Supplementary Fig. 5a ).
Another seven nasal modules and one blood module had expression specifically elevated in V 
Ex
-, n = 147; biologically independent samples. Longitudinal data are plotted with a 95% confidence interval (shaded region) estimated by local second-degree polynomial regression. To assess significance, a linear model was fit with a B-spline basis for a polynomial spline with degree 2 for days after cold onset and ANOVA was run to determine whether exacerbation status was significant.
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NATuRe IMMuNOlOgy in both nasal and blood samples, which contained IRF7, STAT1, STAT2, and numerous antiviral effector molecules; a respiratory epithelium-associated 'cilia/IL-33 response' pathway including IL33, FOXJ1, TLR3, and CDHR3, in association with genes of ciliogenesis, cell-cell adhesion, and ECM adhesion; and a nasal 'heat shock proteins (HSPs)/stress response' module. They also included the nasal macrophage-associated modules 'chemoattraction/cytotoxicity' , 'antigen processing and presentation (APP)' , and 'antigen-presenting cell (APC) co-stimulation' . Each of these modules had the highest expression in V + Ex + events in comparison to the three other groups (FDR < 0.05), with expression in some modules modestly elevated in V Fig. 5b ). These findings demonstrate a multifaceted immune response to viruses that is more intense in viral infections that lead to an exacerbation. Two nasal modules had expression that was specifically decreased in V 
Ex
+ subgroup in comparison to the other three groups (FDR < 0.05), demonstrating specificity of these pathways to nonviral exacerbations. These were each highly associated with squamous percentages. These modules included the largest module in the repertoire annotated as 'keratinization/epithelial development/cell-cell adhesion/tight junctions' , which is composed of 1,041 genes, is enriched for numerous barrier functions, and includes CDH1 (E-cadherin) and FLG (filaggrin). The other two modules were 'tissue kallikreins/keratinization' , which includes seven tissue kallikreins and several proteins and enzymes responsible for cornification, and 'squamous epithelium' ( Supplementary  Fig. 5c ). These findings point to distinct and partially squamous cell-specific initiation of asthma exacerbations triggered in the absence of virus.
These results confirm that the set of core modules are common to both virus-associated and nonviral exacerbations while demonstrating that there is a distinct set of respiratory epithelium and inflammatory cell pathways involved in virus-associated exacerbations in contrast to the predominantly squamous cell pathways underlying nonviral exacerbations.
Sequential immune activation underlying the development of an asthma exacerbation. We next investigated the kinetics of module expression during illnesses in the Ex
+ and Ex -groups relative to baseline values by using local regression to incorporate the timing of observed transcriptional changes relative to the onset of cold symptoms. Expression of genes in the 'SMAD3-related cell differentiation' module was significantly increased in the Ex + group within 1 d of cold onset and was sustained for several days throughout the event (FDR < 0.001; Fig. 4a ). Similarly, expression in the 'lymphocyte proliferation' and 'BCR signaling' modules nadired rapidly in the Ex + group, within 1-2 d of cold symptom onset (FDR < 0.001). These early changes in immune response were followed by slower elevation and later peaks (at approximately day 4) in the expression of genes in the 'eosinophil activation/mucus hypersecretion' , 'ECM production/cell membrane' , and 'EGFR signaling/ cell-cell adhesion' modules, all of which showed a steady increase in expression in the Ex + group in comparison to baseline while showing decreased expression in the Ex -group (FDR < 0.05; Fig. 4a ). These later-peaking modules appear to represent 'effector' functions related to the pathophysiology of exacerbations, and these dynamics demonstrate the sequential pathway activation underlying exacerbation events.
In the V + Ex + subgroup, we observed that expression in the 'cilia/IL-33 response' module peaked rapidly, within 1 d of cold onset, whereas expression in the V + Ex -subgroup of this module decreased throughout the event (FDR < 0.05; Fig. 4b ). Expression ; the lower three quartiles were not statistically different from one another), and they had >50% risk of an exacerbation in the first 30 d after the baseline visit. b, In comparison, Kaplan-Meier analysis demonstrates that baseline FEV 1 predicted (%) does not significantly predict time to the next exacerbation, when individuals are split into those with FEV 1 predicted <80% (n = 21) and those with FEV 1 predicted ≥80% (n = 82) (P = 0.11). The same is true when individuals are split into quartiles according to FEV 1 predicted (P = 0.3; data not shown). All samples shown are biologically independent. Shaded regions represent 1 s.d. log confidence intervals. Plus symbols represent censored observations.
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NATuRe IMMuNOlOgy of the 'type 2 inflammation' module stayed at a stable level in the V + Ex + subgroup, whereas it steadily decreased in the V + Ex -subgroup (FDR < 0.05). The nasal 'type I IFN response' and 'HSPs/ stress response' modules and the macrophage-associated 'chemoattraction/cytotoxicity' and ' APP' pathways each showed peak expression between days 1-3 and expression was significantly increased during both V + Ex + and V + Ex -events; however, V + Ex + events had higher peak expression levels and higher areas under the curve, in line with sustained expression of the genes in these inflammatory pathways at increased levels in V + Ex + as compared to V + Ex -events (FDR values of 0.01-0.19; Fig. 4b ). In the V -Ex + subgroup, we observed that the three squamous-associated pathways had elevated expression on days 1-3 and expression then returned toward baseline levels; however, the model for this comparison was not statistically significant (FDR > 0. 25) .
Through this longitudinal analysis, we discerned kinetic models of the molecular events underpinning cold events that resolves versus those that lead to an exacerbation.
Baseline immune state represents a risk factor for exacerbation. We next investigated how levels of module expression at the baseline healthy visit influence subsequent risk of an asthma exacerbation. We compared module expression levels to the time from baseline to the first asthma exacerbation. Four nasal modules were significantly associated with time to exacerbation (P < 0.05; Supplementary Table 3) . To determine the optimal model, we performed forward stepwise regression with the significant modules. Two of these modules, 'type 2 inflammation' and 'type I IFN response' , each independently contributed significantly to overall model fit (beta coefficient, P < 0.05), and the model incorporating both of these modules showed significantly better fit (ANOVA, P < 0.05) than either univariate model. Specifically, higher expression of the 'type 2 inflammation' module and lower expression of the 'type I IFN response' module were associated with a shorter time to exacerbation. When related to exacerbation probability, an elevated ratio of 'type 2 inflammation' to 'type I IFN response' expression corresponded to a highly significant risk for + and one Ex -event have the same measurement shown for Ex + at baseline and Ex -at baseline. All measurements shown are otherwise biologically independent. Comparisons were performed by using a weighted linear model and empirical Bayes method, including terms for status (Ex -, Ex + pre-CS, and Ex + post-CS), cell percentages, presence or absence of virus, visit, and library sequencing depth with a random effect included for participant. Contrasts were tested for status within and across visits. The term for presence or absence of virus was removed in the analysis limited to V + events.
NATuRe IMMuNOlOgy exacerbation in the short term, with individuals in the highest quartile having a significantly shorter time to exacerbation than individuals in the lower three quartiles (P < 0.001) and >50% risk of an exacerbation in the first 30 d after the baseline visit (Fig. 5a ). This expression ratio was a better predictor of short-term exacerbation risk than any of the collected clinical variables, such as baseline FEV 1 predicted (%) (Fig. 5b) . These results show that a baseline gene expression pattern constituting high expression of nasal type 2 inflammation genes and low expression of type I IFN response genes is a robust predictor of short-term exacerbation risk.
Effects of systemic corticosteroid treatment on the immune response. To examine the effects of systemic corticosteroid administration on immune responses, we studied 30 samples that had been
d).
Corticosteroids induced broad changes in immune pathways, altering the expression of 11 nasal modules and nasal eosinophil and neutrophil percentages, as well as the expression of 6 blood modules and blood eosinophil and neutrophil percentages (FDR < 0.05; Supplementary Table 4) . Notably, expression of only a subset of the core exacerbation-associated modules was significantly altered by systemic corticosteroid use. Expression of genes in the 'eosinophil activation/mucus hypersecretion' and 'SMAD3-related cell differentiation' modules returned to levels equivalent to baseline after initiation of systemic corticosteroids (Fig. 6a) ; however, the other four core exacerbation modules did not show a significant change in expression with systemic corticosteroids. Among the V + Ex + -specific modules, systemic corticosteroid use led to significant reduction of expression only in the ' APP' and 'type 2 inflammation' modules (Fig. 6b) . These results show that systemic corticosteroid treatment affects only a subset of the pathways involved in asthma exacerbations while also affecting multiple other biological processes.
A modular network graph demonstrates the patterns underlying exacerbation types. To facilitate interpretation of results and develop a platform for future comparisons and studies, we generated a cell-module bipartite network by using the entire dataset ( Supplementary Fig. 6a ). This network visually clusters co-associated modules and cell types to help identify co-occurring molecular events, leveraging the high degree of clustering among modules and cell differentials (Supplementary Fig. 6b ).
By using this framework, the similarities and differences between V + Ex + and V -Ex + events are evident (Fig. 7a,b) . The upregulated core exacerbation modules can be seen as common to both Ex + groups, clustering in close association with airway epithelial cells and eosinophils as expected, but also with peripheral blood eosinophils. Specific to V + Ex + events, the upregulated 'cilia/IL-33 response' and 'type 2 inflammation' modules cluster together, demonstrating their close co-association, and near the upregulated core modules. Furthermore, we observe a distinct block of modules representing the type I IFN response as well as APC-related responses that are specific to V + Ex + events, closely associating with nasal macrophages and lymphocytes as well as blood monocytes. In contrast, in V -Ex + events, we observe that the same core modules were upregulated but cluster in association with the three upregulated squamousassociated modules.
The same network can be used to investigate other signals within the dataset; systemic corticosteroid treatment led to a decrease in eosinophils and downregulation of eosinophil-associated modules and two core exacerbation modules, without impacting the other exacerbation-associated modules (Fig. 7c) . Also visible is the increase in airway neutrophils and expression of neutrophilassociated modules.
In conjunction with the previous results, this network analysis facilitates development of a model of the molecular events underpinning a cold event that resolves versus one that leads to an exacerbation and the effects of therapeutic intervention with systemic corticosteroids (Fig. 7d ).
Discussion
Determining pathways by which asthma exacerbations occur in relation to distinct triggers and defining why some upper-respiratory illnesses provoke an exacerbation whereas others do not are critical areas of interest in asthma. We explore these areas through longitudinal transcriptome network analyses of nasal and blood samples from a cohort of exacerbation-prone children. Previous asthma transcriptomic studies have been more limited, defining gene expression levels in relation to stable or active disease sta tes [11] [12] [13] [25] [26] [27] [28] [29] [30] . Our results provide systems-level, data-driven determination of a complex network of molecular responses underpinning asthma exacerbations in comparison to both cold symptoms without exacerbation and stable disease. They provide important granularity for multiple distinct biological pathways, the relationships among these pathways, and their relative kinetics leading to an exacerbation.
Our findings are consistent with several established mechanisms of asthma exacerbation, confirm their importance in a highly relevant human study, and add appreciable new information to advance insight into exacerbation pathogenesis. An important result is the + Ex + events includes a cluster of the core exacerbation modules (outlined in green squares), as well as a cluster of the type I IFN, macrophage-associated, and APC-related modules (dark purple box), the 'cilia/IL-33 response' module, and the 'type 2 inflammation' module (dark purple labels). b, The signal for V -Ex + events also includes a cluster of the core exacerbation modules as well as a cluster of the squamous-associated modules (dark orange box). c, The signal from corticosteroid treatment affects multiple areas of the network, most notably resulting in a marked decrease in clustered nasal and blood eosinophil cell percentages and module expression (magenta box). The bipartite network in each panel demonstrates the co-associations among nasal (light orange) and blood (light purple) modules (squares) and cell percentages (circles). Edges represent significant positive Pearson correlations >0.5, and darker edges indicate higher correlations. Nodes are clustered according to their interconnectedness. For each comparison, significant differences in module expression and cell percentages are colored red (increased) or blue (decreased), with color intensity corresponding to fold change. Modules whose expression was not significantly different (FDR ≥ 0.07) are shown as points rather than squares to simplify the diagram. d, The diagram summarizes the main results of our analysis, showing the key pathways observed related to viral and nonviral exacerbation events. Shown in two green boxes are the annotated molecular functions of the core exacerbation modules, related to upregulation of respiratory epithelium, squamous, and eosinophil responses and downregulation of lymphocyte responses, common to both viral and nonviral cold events that progress to an asthma exacerbation. These are separated into early-response pathways (left) and late/effector pathways (right) on the basis of the results of the longitudinal analysis. Shown in the dark purple box is the distinct set of respiratory epithelium-and inflammatory cell-associated pathways observed only in virus-associated exacerbations. Shown in the dark orange box are the predominantly squamous cell-associated pathways observed only in nonviral exacerbations. The pathways affected by systemic corticosteroid use are labeled. The contrasting responses observed in resolution of a viral upper-respiratory infection are shown at the top.
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NATuRe IMMuNOlOgy identification of the relevance of epithelial-associated SMAD3 signaling as a key early event in exacerbations. SMADs are signaling proteins that are a surrogate for TGF-β activity 31 and are known to have a central role in airway inflammation and remodeling in asthma; SMAD3 is required for airway remodeling in mice 32 . We observe that this pathway is upregulated in exacerbations regardless of the apparent trigger and upregulation is an early, central event in exacerbation development. This observation may represent a mechanism central to the link between repeated exacerbations and decline in lung function 33 , with TGF-β activity inducing SMAD3 signaling within the epithelial-mesenchymal-trophic unit to enhance airway remodeling 34 . Our results support the importance of IL-33 and type 2 inflammation in asthma exacerbations 8 . IL-33 is an alarmin synthesized in response to epithelial damage, including from respiratory viruses 35 , and amplifies innate immune pathways including type 2 inflammation 8, 36 . Although pathogenic in asthma, IL-33 also has a key role in tissue repair 35 , functions we see linked within the 'cilia/ , and CDHR3, a key susceptibility locus for childhood asthma 38 that encodes the protein by which RV-C enters the epithelium, thus suggesting that the IL-33-mediated protection/repair process may leave the epithelium more susceptible to repeated infections. Upregulation of this module was closely associated with expression of the type 2 inflammation module, recapitulating the known interplay between these two key asthma mechanisms 8 . We observe asthma exacerbations that occur in the absence of a virus and are characterized by induction of keratinization, epithelial barrier pathways, and tissue kallikreins, which may represent metaplasia of the epithelium toward keratinized squamous cells, as observed with noxious exposures such as cigarette smoke 39 . Kallikreins generate kinins, including bradykinin, a key mediator of multiple acute responses in asthma that also impacts airway remodeling 40, 41 . Notably, our findings directly relate features of airway epithelial barrier dysfunction to epithelial kallikrein induction in asthma exacerbations. Although we could not identify a definite etiology for these exacerbations, smoke, pollutants, or allergens are possible causes, as each of these can disrupt epithelial integrity and in animal models can lead to production of bradykinin 42, 43 . We demonstrate that high type 2 inflammation and low type I IFN response gene expression in nasal samples at baseline predicts short-term exacerbation risk, building on previous results showing that nasal IL13 expression is associated with exacerbation likelihood 30 . This suggests a specific 'at-risk' immune state, when a child is highly susceptible to exacerbation. Furthermore, our results provide insight into conflicting data regarding antiviral IFN responses in asthma from earlier studies, in which some have shown relative deficiency in IFN responses 44, 45 whereas others have shown normal or excessive responses 46, 47 . Our data show that both observations may be valid; IFN responses may not be consistently diminished or elevated, but rather dysregulated. Low IFN signaling at baseline may enable viral replication and/or epithelial damage during the early phase of infection, which secondarily induces an exaggerated IFN response promoting exacerbation. We show that systemic corticosteroid treatment affects only a subset of exacerbation-associated pathways, in particular those related to eosinophil activation and mucus hypersecretion, type 2 inflammation, and epithelial SMAD3 signaling. The failure of corticosteroids to moderate other pathways, including EGFR signaling and ECM production, may help to explain why corticosteroid treatment has limited efficacy in preventing lung function decline 48 . This result also provides an example of definition of the in vivo molecular effects of therapeutics, which is critical to improving interventional approaches.
A major strength of our study is its prospective design. We captured cold symptoms and natural viral infections as opposed to using viral inoculation or an in vitro model. By using daily symptom monitoring, we captured events at the beginning of symptoms prior to both clinical exacerbation and initiation of systemic corticosteroids, while also capturing follow-up samples to investigate progression of the immune response and the effect of systemic corticosteroids. By using transcriptome network analysis, we were able to investigate our aims in an unbiased manner, leading to the discovery of new findings while also confirming and expanding upon anticipated results. Through serially combining two powerful network analysis techniques, cell deconvolution and WGCNA, in a novel algorithm, we distilled a massive dataset into coherent, statistically rigorous, and biologically meaningful conclusions.
A limitation to our approach was the use of upper-airway samples as a proxy for lower-airway events. Previous work has demonstrated that nasal epithelial expression profiles are globally similar to those of the lower airway 30 and are specifically similar in key pathways, including aspects of remodeling 49 , but there is also evidence of differences in certain immune pathways, including interferon responses 50 . It is possible that we have missed aspects of the lower-airway inflammatory response by not directly sampling the lower airway during illness. However, the clear differences between Ex + and Ex -events and the corresponding decrease in pulmonary functions suggest that our findings reflect molecular pathways directly relevant to the pathophysiology of exacerbations. Paired upper-and lower-airway samples collected in future work can build upon our results. By collecting lavage from the upper airway, we obtained samples that were mixtures of inflammatory and epithelial cells. Given the clear importance of respiratory epithelium in viral infections and asthma, future studies could use epithelial brushings as a means to potentially further define the role of the epithelium in exacerbations.
Our methodology enabled us to obtain significant data and meaningful results from a sample readily collected in a clinical setting with minimal invasiveness. This approach was successfully and safely implemented in children and adolescents from a high-risk population, in which lower-airway sampling is not feasible during an emerging asthma exacerbation. Furthermore, our modular repertoire and network visualization provide a platform to test new comparisons and analyze new datasets. The current study did not investigate specific interventions and is not intended to definitively determine causation. This in vivo platform can be used to investigate the granularity of specific exacerbation subtypes and the effects of therapies anticipated to block specific components of exacerbation pathways.
In conclusion, we have demonstrated the application of transcriptome network analyses as a robust methodology to define networks of immune responses underpinning asthma exacerbations in children. This strategy revealed coordinated epithelial and eosinophil pathways that are upregulated as well as lymphocyte pathways that are downregulated in both virus-associated and nonviral exacerbations. We also found distinct responses in viral and nonviral exacerbation events and identified baseline characteristics associated with susceptibility to exacerbations. Finally, we have developed a new sample collection and analysis platform that can be readily integrated into translational asthma research. Collectively, we anticipate that these approaches will advance understanding of both the efficacy of current and novel intervention strategies and unresponsiveness to these strategies in some treated individuals, thereby leading to a clearer and more comprehensive understanding of asthma exacerbations and how to prevent and treat them.
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Methods Study design and eligibility. This was a prospective, longitudinal case-control study designed to identify changes in gene transcription during cold-associated asthma exacerbations in children. Participants were recruited across nine inner-city sites in Boston, Chicago, Cincinnati, Dallas, Denver, Detroit, New York, St. Louis, and Washington, DC. An individual was eligible for enrollment if he or she was 6 to 17 years of age; was diagnosed with asthma by a clinician more than 1 year prior to recruitment; had at least two asthma exacerbations in the prior year (defined as a requirement for systemic corticosteroids and/or hospitalization); was treated with at least 250 µg of fluticasone delivered by one puff twice daily or its equivalent for those aged 6 to 11 years or treated with at least 250/50 µg of Advair delivered by one puff twice daily or its equivalent for those aged 12 years and older; had a peripheral blood eosinophil concentration of ≥150 cells/mm 3 ; was a nonsmoker; and had a parent or legal guardian who signed written informed consent and, if applicable, signed the assent form, as per central institutional review board (IRB) guidelines.
An individual was not eligible for enrollment if the individual was pregnant or lactating; was receiving treatment with anti-IgE therapy or had received anti-IgE therapy in the previous 3 months; was receiving immunotherapy; had clinically significant abnormalities on complete blood count; was treated with systemic corticosteroids for any medical condition including an asthma exacerbation within the previous 2 weeks; had a cold within the previous 7 d; was participating in an asthma-related pharmaceutical study or intervention study or had participated in such a study within the previous 4 weeks; required greater than 500 µg of fluticasone plus a long-acting beta-agonist delivered by one puff twice daily or its equivalent and/or used oral corticosteroids daily or every other day; had any medical illnesses that in the opinion of the investigators would increase the risk incurred by participating in the study, interfere with measured outcomes, or interfere with performance of study procedures; had concurrent medical problems that required systemic corticosteroids or other immunomodulators; was diagnosed with cancer or had a history of cancer; had plans to move from the area; did not have a primary caretaker that spoke English or Spanish; was a foster child; would not allow management of their asthma for the duration of the study; was not able to perform pulmonary function tests; had known hypersensitivity to any medications used for asthma treatment; or had a life-threatening asthma exacerbation in the previous 2 years.
Ethical compliance. The study complied with all relevant ethical regulations. The study was approved by a central IRB (Western IRB), and a parent or legal guardian for each child signed written informed consent before study procedures were completed. The study is registered on ClinicalTrials.gov under NCT02502890.
Study visits.
Participants meeting eligibility criteria attended a screening and enrollment visit (visit 0). Participants were then followed prospectively for up to two cold events or approximately 6 months after visit 0, whichever occurred first. Participants who reported cold symptoms returned to the clinic for the following visits: visit 1a, which occurred within 3 d of the onset of cold symptoms, and visit 1b, which occurred 4 to 6 d after the onset of cold symptoms. Participants who reported a second set of cold symptoms (occurring at least 2 weeks after the onset of the first cold symptoms and at least 2 weeks after the final dose of systemic corticosteroids was administered for an asthma exacerbation) had additional visits, visit 2a and visit 2b, which were identical in nature to visit 1a and visit 1b. Visits were defined as an exacerbation event (Ex + ) if the participant was treated by a physician with systemic corticosteroids in the 10 d following onset of cold symptoms; otherwise, they were defined as a cold without exacerbation (Ex -). Criteria for the initiation of systemic corticosteroids were as previously specified in Inner-City Asthma Consortium trials 4 . Participants were treated with systemic corticosteroids if albuterol was needed by inhaler or nebulization for more than six individual treatments over 24 h; moderate-to-severe wheeze, cough, shortness of breath, and/or chest tightness or pain occurred for at least 5 of the preceding 7 d; symptoms of wheeze, cough, shortness of breath, and/or chest tightness or pain were severe enough to place a participant in his or her 'red zone' on their asthma action plan 4 and did not significantly improve after three doses of albuterol; there was an unscheduled visit for acute asthma care requiring repeated doses of albuterol (to a clinician's office, urgent care, or emergency department); or hospitalization was needed for asthma. Additional visits included visit 3 (3 months after visit 0) for medication management and a final study visit, visit 4, which occurred approximately 2 weeks after the second set of cold visits (2 weeks after visit 2b) or 6 months after visit 0 if the participant did not have two sets of cold visits.
Throughout the study, an internet-based asthma and cold symptom diary was accessed by each participant by using a handheld device provided at enrollment. The diary asked participants to assess cold and asthma symptoms on a four-point visual scale. Participants were asked to complete the diary on a daily basis, and if symptoms of a cold or asthma exacerbation were reported a participant was contacted on the same day or the next weekday by study coordinators to schedule follow-up visits 1a and 1b or visits 2a and 2b. Diary compliance was monitored throughout the study, weekly reminders were provided, and study coordinators contacted participants directly to assess symptoms if compliance was low.
At ) 51 . Treatment was supervised by a study clinician. The study clinician prescribed initial, appropriate concomitant asthma therapies and provided a written asthma action plan for each participant at each visit. The regimen was adjusted as necessary throughout the duration of the study on the basis of the principles in the EPR3 guidelines.
Clinical evaluations conducted at each visit included assessment of the following: vital signs and growth parameters (height, weight, pulse rate, temperature, and blood pressure); medical history and physical examinations; exhaled nitric oxide according to American Thoracic Society guidelines; pulmonary function according to American Thoracic Society and European Respiratory Society guidelines; and a questionnaire, including information on demographics, asthma and allergy history and medication use, asthma exacerbation history, asthma symptoms and healthcare utilization, cold symptoms, concomitant medications, and adverse events.
Allergen skin testing was performed at visit 3 or 4 by using the prick technique with the GreerPick system. Allergens that were assessed included mouse, dog, cat, rat, dust mite, cockroach (American and German), Alternaria, Aspergillus, ragweed mix, Eastern 8 tree mix, K-O-T grass mix, Bermuda grass, and/or juniper (for some sites only). Skin testing was performed on participants after at least 5 d in which they did not use antihistamines.
Sample collection. Blood. Blood samples were collected via peripheral venipuncture at visits 0, 1a, 2a, 1b, and 2b to collect RNA (Tempus Blood RNA tubes, Thermo Fisher Scientific) and to assess complete blood counts with automated differentials. RNA samples were vortexed for 10 s and then frozen at −20 °C until shipment to a central processing facility. Blood differentials were processed by each site's CLIA-approved lab facility through standard methods.
Nasal blow. Nasal mucus samples were obtained at visits 0, 1a, and 2a for respiratory virus assessment as previously described 52, 53 . Briefly, participants were instructed to exhale forcefully through the nose into a tissue to clear excess mucus. Holding one nostril shut, saline was sprayed into the other nostril and the participant then blew from that nostril into a collection 'baggie' . The procedure was repeated with the opposite nostril while using the same baggie. M4RT medium (Thermo Fisher Scientific) was added to the collection baggie, and the contents were mixed and stored at −80 °C until shipment.
Nasal lavage. Nasal lavage samples were collected at visits 0, 1a, 1b, 2a, and 2b. Nasal lavage was collected immediately after a nasal blow procedure as follows. Holding their head level, the participant squeezed sterile sodium bicarbonatebuffered normal saline from a 240-ml sinus rinse bottle (NeilMed Sinus Rinse) into the right nostril while a 50-ml Falcon collection tube (tube 1) was held under the left nostril, until 15-20 ml of fluid was collected from the left nostril. Then, occluding the right nostril, the participant gently blew the left nostril several times into a separate 50-ml collection tube (tube 2). Next, while the participant held their head backward at an approximately 45° angle, 5-10 ml of saline from the sinus rinse bottle was squeezed into the right nostril and held in the nose for 2-3 s, after which the participant tilted their head forward and allowed the saline to drip into collection tube 2. This procedure was repeated for the left nostril while using a third collection tube (tube 3) and tube 2. The entire procedure was repeated for nostrils. Samples were kept on ice during and after collection.
After collection, each tube was vortexed for 10 s and consolidated. Samples were centrifuged at 1,300g for 10 min at 4 °C. All but ~10 ml of supernatant was removed and discarded. Cell pellets were resuspended in the remaining supernatant. The resuspended pellets were passed through a 100-micron strainer (MACS SmartStrainer). The strained fluid was gently mixed by pipette to homogenize the sample. 1.3 ml was removed and set aside for slide generation, and the remainder was centrifuged at 1,300g for 10 min at 4 °C, the supernatant was removed, and 1 ml of RNAprotect Saliva Reagent (Qiagen) was added and the pellet resuspended. Samples were kept on ice and/or at 4 °C during processing.
Urine. Urine was collected at each visit for urine pregnancy testing (for females who had reached menarche) and for urine cotinine testing to measure exposure to environmental tobacco smoke.
Virology. Nasal blow samples were used to assess respiratory viruses by multiplex PCR and partial sequencing to identify RV species and types as previously described 52, 53 . Nasal cell differentials. The reserved 1.3 ml of nasal material was used to generate six slides with a Cytospin 4 cytocentrifuge (Thermo Fisher Scientific). Two slides were generated with 500 µl each, two slides with 100 µl each, and two slides with 10 µl each, following the manufacturer's protocol. Slides were air dried for 10 min and then fixed and stained with a Hema3 Stain Set (Thermo Fisher Scientific) according to the manufacturer's protocol.
Nasal cell differentials were performed by manual review of six Cytospin slides per sample, followed by manual read of the slide with the optimal cell 54 morphological criteria were used to identify these six cell types in the differential cell analysis: (i) neutrophils: segmented bi-, tri-, or multilobed nucleus, pale cytoplasmic staining, and indistinct cytoplasmic borders; (ii) lymphocytes: high nuclear-to-cytoplasmic ratio and small size in relation to macrophages; (iii) macrophages: vacuolated cytoplasm, round shape, variable cell size, and often eccentric nuclei; (iv) eosinophils: cytoplasm filled with intensely pink-stained granules and bi-, tri-, or multilobed nucleus; (v) respiratory epithelium cells: columnar or variable shape, relatively darker cytoplasmic staining as compared to squamous cells, and/or the presence of cilia and/or a terminal nucleus; and (vi) squamous cells: large size, high cytoplasmic-to-nuclear ratio, and bland cytoplasmic staining. Two sequential counts were performed on each sample. All slides were read by a single experienced individual who was blinded to clinical and outcome variables.
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RNA-seq library preparation and sequencing. Total RNA was isolated from nasal cell pellets in RNAprotect Saliva Reagent (Qiagen). Samples were centrifuged for 10 min at 10,000g, supernatant was removed, and the cell pellet was resuspended in 350 μl of RLT buffer with 1% β-mercaptoethanol. Samples were vortexed for 1-2 s, sonicated for 30 s, spun through a QIAshredder column (Qiagen), and then extracted with an RNeasy MinElute spin column (Qiagen) following the manufacturer's protocol.
Total RNA was isolated from whole-blood lysate by using the MagMAX for Stabilized Blood Tubes RNA isolation Kit for Tempus Blood RNA Tubes (Thermo Fisher Scientific) following the manufacturer's protocol. Globin mRNA was depleted by using GLOBINclear (Thermo Fisher Scientific).
RNA quality was assessed by RNA electrophoresis (Agilent) and NanoDrop 1000 (NanoDrop Products, Thermo Fisher Scientific). Sequencing libraries were constructed from total RNA with TruSeq RNA Sample Preparation Kit v2 (Illumina) and clustered onto a flow cell by using the cBOT amplification system with the HiSeq SR v4 Cluster Kit (Illumina). Single-read sequencing was carried out on a HiSeq 2500 sequencer (Illumina), by using the HiSeq SBS v4 kit to generate 58-base reads, with a target of approximately 10 million reads per sample. Samples were sequenced in four batches and repeated samples were used across batches to allow assessment for batch effects. Resulting bcl files were deconvoluted and converted to fastq format by using Casava from Illumina. fastq files were aligned to the Ensembl version of the human genome (GRCh38; GenBank assembly GCA_000001405.15) with TopHat (version 1.4.1) 55 . The single-paired flag was set to 'single' , while all other TopHat parameters were set to default. HTSeq-count 56 was used to generate gene counts with the mode set to 'Intersection (nonempty)' and the minimum alignment quality set to 0; parameters were otherwise set to default. In quality-control analysis, samples were kept that had >0.3 million counts, >0.66 percent alignment, and median CV coverage of <1.5. Genes were filtered to include those that had a trimmed mean of M value (TMM) normalization count of at least 1 in at least 10% of libraries and were classified as protein coding with BioMart 57 . Each of the four sample batches was independently normalized within the batch via TMM normalization and values were transformed to log 2 (counts per million) along with observations level weights by using voomWithQualityWeights from the limma R package 58, 59 . Batch processing did not contribute variability in gene expression due to batch effects, so the replicate with the highest percentage alignment was included for analysis and the other replicates were removed. The final dataset included 374 nasal samples composed of 13,672 genes and 387 blood samples composed of 13,316 genes.
Module definition and validation. Cell-type-associated gene coexpression modules were generated by using samples collected from the first fall enrollment season (first two batches of processed samples), which included 42 participants capturing 59 cold events (146 nasal lavage and 176 peripheral blood samples).
Cell type deconvolution was performed by assigning genes to cell types on the basis of statistically significant positive Pearson correlation between gene expression and cell differentials according to CellCODE 60 . Genes without a cell type assignment were considered to not be cell type specific. For the nasal samples, of the 13,672 unique protein-coding genes, cell type deconvolution associated 1,525 genes with neutrophils, 1,192 genes with lymphocytes, 788 genes with macrophages, 672 genes with eosinophils, 241 genes with epithelium cells, and 1,058 gene with squamous cells. 455 genes were associated with two or more cell types, and 8,744 genes were not associated with a specific cell type. For blood samples, of the 13,316 genes, cell type deconvolution associated 2,069 genes with neutrophils, 1,699 genes with lymphocytes, 127 genes with monocytes, 119 genes with eosinophils, and no genes with basophils. 59 genes were associated with two or more cell types, and 9,360 genes were not associated with a specific cell type.
After genes were either assigned to a cell type or left unassigned, WGCNA 61 was run on each separate cell type and the unassigned genes within each sample type, giving a total of 52 nasal modules and 42 blood modules. The parameters used were minCorKME = 0.7 and minKMEtoStay = 0.5, indicating that a module must have a block of genes with Pearson correlation of at least 0.7 to be considered a module and all genes in a module must have a Pearson correlation of at least 0.5 with the module's eigengene. Module-level expression values were calculated by using the geometric mean for the genes assigned to a module. Coherence of these modules was assessed at completion of the study across the entire sample set spanning both years of study (374 nasal samples and 387 blood samples). We calculated gene-cell type assignments, module-cell type Pearson correlations, and intramodular Pearson correlations and compared these values to the values from module generation. These values were consistent with the levels seen in defining modules and were highly significant ( Supplementary Fig. 7a ), demonstrating the stability and reproducibility of this modular repertoire for the population (severe asthmatics) and variables (baseline, upper-respiratory illness, and exacerbation) of interest. Final cell assignment for each module was based on significant Pearson correlation of the module and cell differentials in the full dataset. Seven nasal modules were associated with neutrophils, five were associated with lymphocytes, five were associated with macrophages, five were associated with eosinophils, eight were associated with epithelium cells, and eight were associated with squamous cells. Five blood modules were associated with neutrophils, seven were associated with lymphocytes, two were associated with monocytes, and two were associated with eosinophils. All analyses were run in R.
Pathway analysis. The biological function of modules was investigated by using the Database for Annotation, Visualization, and Integrated Discovery (DAVID) version 6.8 62, 63 . This database uses a modified Fisher's exact test to identify specific biological or functional categories that are over-represented in gene sets in comparison with a reference set (the default human genome was used as the reference set). Each module was submitted, and all available enrichment categories were downloaded and ranked according to FDR. Modules were considered to have significant enrichment if one or more of the DAVID default categories showed enrichment with FDR < 0.05. 87% of modules showed enrichment for one or more DAVID category terms. Functional annotation clusters were also generated by using all default categories in DAVID.
STRING version 10.5 64, 65 , which is a database of known and predicted proteinprotein interactions, was used to determine the interaction networks for each module. All STRING interaction sources were used, and a minimum interaction score or 0.15 was required for a gene to be included within a network. An interaction network was significant if its protein-protein interaction enrichment P value was <0.05, meaning it had more interactions than expected from a set of proteins of the same size drawn randomly from the human genome. Cytoscape version 3.5.1 66 was used to draw interaction networks according to a prefuse forcedirected layout by using the combined interaction score exported from STRING. The size of each gene was made proportional to the number of interactions in the network as a percentage of the maximum number of interactions for any node in that network. Unconnected nodes were excluded. A summary annotation of each module was derived from manual inspection of a module's cell type assignment, functional enrichment, and interaction network.
Bioinformatic analyses.
To determine primary sources of variability in module expression, principal-component analysis was run and the first five principal components were correlated (Pearson) to clinical and demographic variables to determine the most important sources of variability in the data ( Supplementary  Fig. 3 ). This demonstrated that cell percentages, presence or absence of virus, and visit were each associated with much of the variability in nasal and blood samples. The difference between Ex + and Ex -events was tested by using a weighted linear model (limma in R) and empirical Bayes method 59 . The primary model included terms for exacerbation status, cell percentages, presence or absence of virus, and visit number (1a/2a or 1b/2b) as well as library sequencing depth. Because multiple samples came from each participant, a random effect was included for participant.
The model for nasal samples, with y representing each module's expression, was 
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Multiple-testing correction was performed by using the Benjamini-Hochberg method and modules with FDR < 0.05 were considered significant for all comparisons. Other FDR values that were close to significance are also reported in the text.
The same model was used for the paired and unpaired subgroup analyses. For the sensitivity analysis, we performed bootstrapping with random subsets of 80% of participants over 200 iterations.
For the subgroup comparisons (V
, presence or absence of virus was removed from the model and we ran ANOVA to determine an overall significance value and then pairwise comparisons to determine significant differences across groups. For the corticosteroid analysis, the model included the same variables of cell percentages, presence or absence of virus, visit, and library sequencing depth and then tested contrasts for differences in status (Ex -, Ex + pre-CS, and Ex + post-CS) within a visit and across visits. The term for presence or absence of virus was removed in the analysis restricted to V + events. For the longitudinal analysis, we used local polynomial regression fitting (loess) in R, with a degree of smoothing of 1.5 and a polynomial degree of 2. To assess significance, a linear model was fit with a B-spline basis for a polynomial spline with degree 2 for days after cold onset, and ANOVA was run to determine whether exacerbation status was significant.
To study the predictive capabilities of gene expression at the visit 0 baseline, healthy visit, a univariate linear model was built to compare time to exacerbation and each module's expression. Time to exacerbation was defined as the time in days from visit 0 to the first reported exacerbation for each individual, whether or not a participant returned for part a and/or b associated with that particular illness. For participants who did not experience an exacerbation during the study, time to exacerbation was censored to the length of enrollment in the study. Two individuals reported an exacerbation at a later time on the same day as visit 0 and so were excluded from this analysis. Forward stepwise regression was performed with only the significant modules from the univariate analysis in comparison to the time to exacerbation. We selected the model providing the lowest Akaike information criterion that had significant P values for each beta coefficient, which was a linear combination of two modules. Samples were divided into quartiles according to their scaled combined expression value for the two modules. A Kaplan-Meier curve showing the exacerbation probability over time was fit to the data splitting individuals according to quartile. The lower three quartiles overlapped and were each significantly different from the top quartile, and they were therefore combined. For comparison, a Kaplan-Meier curve was generated on the basis of FEV 1 predicted (%) split at 80% or split by quartile. For the KaplanMeier curves, time was censored at 100 d for display purposes, but the results are similar when using the entire length of follow-up.
All analyses were run in R.
Resources, public data, and analysis code. To present the data and methodology from this study as a resource to the research community, we have made all study data and R code publicly available (see "Data availability" and "Code Availability"). The open source code is also annotated to demonstrate how additional secondary analyses of interest beyond the scope of this manuscript can be performed. Furthermore, we include the R code necessary to generate module expression values for the modular repertoire defined in this manuscript from novel gene expression datasets and run analogous comparisons to those described in this study. Collectively, these resources allow a researcher to readily reproduce the findings of this study, perform secondary analyses within this dataset by using other clinical variables of interest, and apply the modular repertoire defined within this study to new datasets relevant to asthma or other disease states of interest.
Bipartite network. Module gene expression levels and cell differentials from all nasal and blood samples were combined and pairwise Pearson correlations were determined. Because respiratory epithelium and squamous cells were highly correlated in the data, they were summed for this analysis. Hierarchical clustering was performed to create a correlation heat map. A bipartite network was drawn by using Cytoscape version 3.5.1 66 according to a prefuse force-directed layout with all significant pairwise correlation values with FDR < 0.05. Comparisons were overlaid onto the network by coloring significant modules according to fold-change values and shrinking the non-significant modules.
Statistics for clinical data. Categorical variables were compared between Ex + and Ex -events by using generalized linear mixed models assuming a multinomial distribution, with a random effect for participant to account for correlation between values from the same participants. In cases of non-convergence of the model, Fisher's exact test was used and within-participant correlation was not accounted for. Summaries are displayed as percentage (count). Continuous variables were compared between Ex + and Ex -events by using generalized linear mixed models assuming a normal, log-normal, or Poisson distribution as appropriate, with a random effect for participant to account for correlation between values from the same participant. For comparisons made while assuming a log-normal distribution, values of 0 were set to 0.05 prior to model fitting. Summaries are displayed as the median (first quartile, third quartile). All P values reported are considered to be descriptive and no adjustments for multiple comparisons were made. SAS version 9.4 software (SAS Institute) was used for all analyses.
Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Data availability
The study data and R code to support the findings of this study have been made publicly available. The raw RNA-seq fastq data and minimum information about a high-throughput nucleotide sequencing experiment (MINSEQE) have been deposited to the Gene Expression Omnibus (GEO) with accession numbers GSE115824, GSE115770, and GSE115823. All metadata from the study cohort have been deposited to ImmPort with accession number SDY1387.
Code availability
The R code for all analyses in this manuscript has been annotated and deposited as open-source code in GitHub at https://github.com/BenaroyaResearch/Peds_ Asthma_Modules.
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Software and code
Policy information about availability of computer code Data collection RNA sequencing bcl files were deconvoluted and converted to fastq format using Casava from Illumina. Fastq files were aligned to the Ensembl version of the human genome (GRCh38) (GenBank assembly accession id GCA_000001405.15), using TopHat (version 1.4.1). The single-paired flag was set to "single," while all other TopHat parameters were set to defaults. HTSeq-count was used to generate gene counts with mode as "Intersection (nonempty)" and minimum alignment quality set to 0 and otherwise set to default parameters.
Data analysis
All RNA sequencing analysis was completed using R versions 3.4.3 and 3.4.4 and the packages referenced in the manuscript. Network graphs were generated using Cytoscape version 3.5.1. Clinical data analysis was completed using SAS version 9.4.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
-Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability RNA-sequencing data were deposited to the National Center for Biotechnology Information Gene Expression Omnibus with accession number GSE115824. All metadata from the study cohort have been deposited to ImmPort with accession number SDY1387. Data will be made public at the time of publication of the manuscript.
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Sample size
Sample size was determined using the R package RNASeqPower and confirmed using the R package PROPER. The following assumptions were made: An average RNA sequencing depth of 10 million reads per library, a type I error rate of 0.05 after multiple testing correction using the Benjamini-Hochberg procedure, and a biological CV for samples ranging between 0.20 and 0.45. The biological CV for samples was based on publicly available microarray data, which was then scaled to the extra variation expected in RNA sequencing data based on the publication "Utilizing RNA-Seq data for de novo coexpression network inference." (PMID: 22556371). The target study sample size was selected to allow us to detect effect sizes of at least 1.50 and higher with 80% power. Our enrollment target was set at 220 participants and our exacerbation event target was set at 32 exacerbations. The power calculation was approved by a NIAID statistician independent of the project.
Data exclusions For data quality control, RNA sequencing data was retained only for samples that had > 0.66% counts aligned to the human genome, a median CV coverage < 1.5, and > 0.3 million counts. Individuals were excluded from the analysis if they did not report any cold events during the study, did not return to clinic for any cold events, or did not have any samples collected during cold events that produced RNA-sequencing data meeting these quality control metrics (see figure 1) . From the RNA-sequencing data, genes were filtered to include only those that had a trimmed mean of M values (TMM) normalization count of at least 1 in at least 10% of libraries and were classified as protein coding using BioMart.
Replication
To cross validate our primary outcome results we did each of the following: 1) The cohort was split into a prespecified paired and unpaired analysis according to a predefined statistical analysis plan and the primary outcome calculated for each; 2) A bootstrap sensitivity analysis was performed though iterative subsetting of the full population. Each of these confirmed the primary outcome as presented in the manuscript.
Randomization For the primary outcome, individuals/samples were organized into groups according to whether they were collected from individuals during cold symptom events that progressed to an asthma exacerbation defined as clinical symptoms that resulted in systemic corticosteroid use within 10 days of cold symptom onset, versus those events that resolved without treatment with systemic corticosteroids. The requirement for systemic corticosteroids and hence the group classification was monitored by an NIAID study manager independent of the study analysts. The group classification was provided to the analysts at the time of data analysis, and the analysis followed a prespecified statistical analysis plan. For the secondary outcome, individuals/samples were further subgrouped into virus associated or not virus associated depending on whether a virus was detected in the associated nasal lavage sample collecting during that cold symptom event. This subgrouping and secondary outcome was also done according to a prespecified statistical analysis plan.
Blinding
Group allocation was provided to the analysts at the time of data analysis and analyses were conducted according to a prespecified statistical analysis plan.
Reporting for specific materials, systems and methods
We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response. 
Human research participants
Policy information about studies involving human research participants
Population characteristics
An individual was eligible for enrollment if he or she: was 6 to 17 years of age; was diagnosed with asthma by a clinician greater than 1 year prior to recruitment; had at least 2 asthma exacerbation in the prior year (defined as a requirement for systemic corticosteroids and/or hospitalization); was treated with at least fluticasone 250 mcg 1 puff twice daily or its equivalent for those aged 6 to 11 years, or treated with at least Advair 250/50 mcg 1 puff twice daily or its equivalent for those aged 12 years and
